After an Alzheimer's Diagnosis: Building the First Treatment Plan

After a diagnosis of Alzheimer's disease, it is understandable to want to start every available treatment immediately. A more useful first plan establishes the diagnosis and stage, identifies the priorities that matter now, and explains what can begin safely. Some people will discuss symptom medication and assessment for an amyloid antibody. Others first need attention to nutrition, heart rhythm, sleep, medicine errors, or unresolved diagnostic questions. The initial prescription is only one part of a plan that must work at home. NIA treatment information

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Ask whether the diagnosis is mild cognitive impairment due to Alzheimer's or Alzheimer's dementia that is affecting independence. Is it currently a clinical diagnosis, or has relevant pathology been demonstrated? Are vascular, mood, or other contributors also suspected? These distinctions can change the next investigations and the treatment discussion. Not every person with MCI has Alzheimer's, and a regimen used for established dementia should not be copied automatically. DETeCD-ADRD diagnostic and disclosure guidance
For Alzheimer's-related MCI or mild dementia, it may be appropriate to ask whether further assessment for an amyloid-directed antibody is worthwhile. This discussion need not wait until a symptom medicine has completely failed: the evidence and eligibility are linked to the clinical population rather than a universal sequence of failed tablets. However, discussing the option is different from proceeding with the first dose.
The written plan should identify each medicine and its current instructions, the next review, what to observe, and how to obtain help outside ordinary clinic hours. If tests remain outstanding, specify who will explain them. A patient receiving an antibody should have the treatment history available for emergency assessment of new neurological symptoms. New confusion in someone using other treatments also deserves consideration of acute causes rather than automatic attribution to Alzheimer's.

Quick answer

Full guide

Clarify the diagnosis before leaving the appointment

Ask whether the diagnosis is mild cognitive impairment due to Alzheimer's or Alzheimer's dementia that is affecting independence. Is it currently a clinical diagnosis, or has relevant pathology been demonstrated? Are vascular, mood, or other contributors also suspected? These distinctions can change the next investigations and the treatment discussion. Not every person with MCI has Alzheimer's, and a regimen used for established dementia should not be copied automatically. DETeCD-ADRD diagnostic and disclosure guidance

The patient needs time to hear and respond to the information. A relative can help record the discussion without excluding the person from it. If too much has been covered, request a short written account of what is established, what remains uncertain, and the next action. For someone returning home after a consultation in China, a clear clinical explanation is much more useful to the local doctor than a translated disease name alone.

Choose priorities that are concrete enough to review. The patient may want to keep attending a familiar activity, while the family is concerned about duplicate medicine doses or poor sleep. Both concerns can be included. The plan should make clear whether a treatment aims to help a symptom, slow clinical decline in a suitable population, or reduce an immediate practical risk.

Review existing medicines before adding another

List every medicine by generic name, actual use, and purpose, including nonprescription sleep aids, allergy remedies, pain medicines, and supplements. Some can worsen cognition or sedation, and some can interact with a proposed treatment. Different brands may contain the same ingredient; a combination product can overlap with a separate tablet. The prescriber and pharmacist need to know what is actually taken rather than only what appears on an old prescription.

If doses are already being missed or repeated, decide who will check administration. A pill organizer helps some people but is not sufficient for everyone. The person may forget that a compartment was already opened or take an additional dose from the original packet. A named caregiver, a simple record, and a refill process can make treatment more reliable. Do not independently stop necessary cardiovascular or other chronic medicines while trying to simplify the list. NIA advice on medication management in cognitive impairment

Discuss an appropriate symptom medicine

Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are common options for symptoms of Alzheimer's dementia. The choice depends on the stage, health profile, tolerability, practical administration, and locally applicable product information. These are alternatives to consider rather than three drugs to start together. A history of gastrointestinal bleeding, poor appetite or low weight, fainting, or a heart rhythm problem can be relevant. NICE pharmacological recommendations

The clinician sets the starting regimen and any later titration. A lack of visible improvement during the first few days is not a reason to increase the dose independently. Similarly, another patient's higher dose is not an appropriate starting point. For donepezil, gastrointestinal symptoms, appetite loss, dizziness, or sleep changes should be communicated, while fainting, a markedly slow pulse, chest pain, or signs of gastrointestinal bleeding require timely assessment. The review should distinguish an adverse effect that needs action from a tolerable transient symptom rather than advising the family to endure everything. Donepezil drug information

Before treatment, note the difficulties that are already present. This helps avoid assuming that every symptom afterward is caused by the new medicine. Equally, a new symptom beginning after initiation or a dose change should not be dismissed as inevitable dementia progression. Timing, severity, and effects on eating, mobility, or daily participation can guide the clinical review.

Make sure the formulation is usable at home

Swallowing difficulty, adherence, and gastrointestinal tolerance can affect formulation choice. Modified-release, dissolving, liquid, and transdermal products have different instructions. Ask the pharmacist before splitting or crushing tablets or substituting one formulation for another. A product that seems convenient is useful only if the patient and caregiver can administer it correctly.

If rivastigmine patches are selected, the caregiver should demonstrate the replacement process and know how to check for an old patch before applying another. Patches can still cause systemic adverse effects and skin reactions. They are not a medication-free option. Ask what to do if a patch is missed, falls off, or treatment has been interrupted. Extra patches should not be used to compensate for omitted treatment, and restarting after a longer interruption may require professional instructions. Rivastigmine transdermal information

The same principle applies to oral medicines: clarify missed-dose and interruption advice at the outset rather than improvising during a weekend or journey. Keep the instructions with the medication list. If the person can no longer swallow safely, the solution is clinical and pharmacy review, not automatically crushing all tablets into food.

Memantine is not an automatic addition for every new diagnosis

Memantine is commonly considered for symptoms in moderate to severe Alzheimer's and may be combined with a cholinesterase inhibitor according to stage and the existing regimen. A recent diagnosis does not necessarily mean the disease is mild, but a desire for a more comprehensive prescription is not enough reason to start multiple agents in everyone. The doctor should explain the rationale and what will be reviewed. NICE stage-related treatment guidance

Kidney problems and the full medicine list should be disclosed. Dizziness, sleepiness, confusion, or constipation may affect safety and should be recorded in relation to initiation or dose changes. Instructions vary with formulation and jurisdiction. A foreign drug-information page is helpful background but does not replace the prescription for the actual product dispensed. Memantine drug information

Discuss antibody assessment while the relevant stage is clear

For Alzheimer's-related MCI or mild dementia, it may be appropriate to ask whether further assessment for an amyloid-directed antibody is worthwhile. This discussion need not wait until a symptom medicine has completely failed: the evidence and eligibility are linked to the clinical population rather than a universal sequence of failed tablets. However, discussing the option is different from proceeding with the first dose.

The assessment includes confirmation of relevant pathology, MRI findings, other medicines, medical risks, and the capacity to undergo monitoring. The patient and caregiver should understand the expected average slowing of decline, the possibility of ARIA and other harms, and the practical burden. Symptom medicines and antibodies have different purposes, so they should not be presented as interchangeable rungs on a single ladder. Current lecanemab prescribing information

The choice may change if bleeding-related risks are substantial or the necessary follow-up cannot be delivered. If treatment is declined or deferred, retain a plan for review and supportive care. That decision does not mean there is nothing to offer. It may reflect the person's priorities or a balance of benefit and burden that differs from another patient's.

Verify the real treatment arrangements in China

As of this article's September 9, 2026 review, formal announcements include Chinese approval of donanemab for the relevant early symptomatic population. On September 3, 2026, Eisai and Biogen also announced approval in China of subcutaneous lecanemab for initiation, with launch described as a subsequent plan. A first appointment should establish which formulation the hospital can actually provide. Approval in the news does not make immediate supply universal. Donanemab China announcement, Subcutaneous lecanemab China announcement

Before starting, confirm access to MRI, the clinician responsible for reading it, arrangements for new symptoms, and how later medicines and costs will be handled. For an international patient, identify the clinician who can continue care after return home. Successfully arranging the first administration does not establish a sustainable course. If local prescribing or monitoring remains unresolved, the two services need to coordinate before initiation is treated as a settled plan.

Keep home observations short and useful

Select a few activities that matter to the patient. Examples include the amount of prompting needed for a familiar morning routine, participation in family conversation, or the effect of night waking on both patient and caregiver. Record relevant tolerability concerns such as appetite, weight, or unsafe dizziness. A brief consistent record is more useful than repeatedly examining the patient or arguing over answers to memory questions.

The first follow-up often checks whether the regimen is being used as intended, whether side effects have emerged, and whether the initial assumptions still fit. It may be too early to assess the longer-term functional result. A single better day, one correct answer, or no obvious improvement within a week cannot independently establish success or failure. Ask in advance what the clinician expects to learn at the first review and what requires earlier contact.

Begin practical support alongside medication decisions

Maintain familiar routines where possible, break instructions into manageable steps, and address discomfort, hearing, vision, and sleep issues. If agitation or resistance appears, look for fear, environmental confusion, pain, or another unmet need before assuming that sedation is the answer. Caregivers need guidance on when to prompt, when to assist, and which tasks now require supervision. Retaining enjoyable activities keeps the plan connected to the person's life.

Discuss independent outings, driving, finances, and medication use before a crisis occurs. A diagnosis does not automatically determine the same restriction for every activity, but neither should safety be postponed until an accident. Assessment should take account of actual ability and local requirements. The person's preferences for future support are easier to discuss while they can participate. Caregiver exhaustion, inadequate sleep, or lack of someone to take over should be included as present problems, rather than treated as matters for much later.

Leave with instructions that can be followed

The written plan should identify each medicine and its current instructions, the next review, what to observe, and how to obtain help outside ordinary clinic hours. If tests remain outstanding, specify who will explain them. A patient receiving an antibody should have the treatment history available for emergency assessment of new neurological symptoms. New confusion in someone using other treatments also deserves consideration of acute causes rather than automatic attribution to Alzheimer's.

The family does not need to resolve every future decision at the first visit. It does need to understand what happens during the coming week and whom to contact if events depart from the plan. Treatment can be adjusted as the clinician learns more about tolerability and everyday needs. A sound starting point is a coordinated diagnosis, prescription, support arrangement, and follow-up process that the household can actually carry out.